Anti-Xa and anti-IIa drugs alter international normalized ratio measurements: Potential problems in the monitoring of oral anticoagulants

Clinical and Applied Thrombosis/Hemostasis

Volumn 10, Issue 4, 2004, Pages 301-309

  Tobu, Mahmut ^a   Iqbal, Omer ^a   Hoppensteadt, Debra ^a   Neville, Brian ^a   Messmore, Harry L ^a   Fareed, Jawed ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

International normalized ratio; Pentasaccharide; Prothrombin time; Recombinant hirudin; Warfarin

Indexed keywords

2 [4 [(1 ACETIMIDOYL 3 PYRROLIDINYL)OXY]PHENYL] 3 (7 AMIDINO 2 NAPHTHYL)PROPIONIC ACID; 4 [(2 AMIDINO 1,2,3,4 TETRAHYDRO 7 ISOQUINOLINYLOXY)METHYL] 1 (4 PYRIDINYL) 4 PIPERIDINECARBOXYLIC ACID; ANTICOAGULANT AGENT; ARGATROBAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; EFEGATRAN; FONDAPARINUX; IDRAPARINUX; ORAL ANTIDIABETIC AGENT; PENTASACCHARIDE; PROTHROMBIN; PROTHROMBIN A; PROTHROMBIN A INHIBITOR; RECOMBINANT HIRUDIN; UNCLASSIFIED DRUG; WARFARIN;

ANTICOAGULANT THERAPY; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONCENTRATION RESPONSE; DRUG EFFECT; DRUG MONITORING; HUMAN; IC 50; INTERNATIONAL STANDARD UNIT; MEDICATION ERROR; MONOTHERAPY; NORMAL HUMAN; PRIORITY JOURNAL; PROTHROMBIN TIME;

ADULT; ANTICOAGULANTS; BLOOD CELLS; DIAGNOSTIC ERRORS; DRUG EVALUATION; DRUG INTERACTIONS; DRUG MONITORING; FACTOR XA; HUMANS; INDICATORS AND REAGENTS; INHIBITORY CONCENTRATION 50; INTERNATIONAL NORMALIZED RATIO; MEDICAL ERRORS; PROTHROMBIN; PROTHROMBIN TIME;

EID: 6344254762     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/107602960401000402     Document Type: Article

References (22)

1. Quick AJ. Prothrombin time in hemophilia and in obstructive jaundice. J Biol Chem 1935;109:73.
2. College of American Pathologists Coagulation Survey set. CG2-C. Northfield, IL: College of American Pathologists, 1997.
3. Hirsh J, Dalen J, Anderson DR, et al. Oral anticoagulants: Mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001;119:8S.
4. Sevitt S, Galagher NG. Prevention of venous thrombosis and pulmonary embolism in injured patient. Lancet 1959;II:981.
5. Francis CW, Marder VJ, Evarts CM, et al. Two-step warfarin therapy: prevention of postoperative venous thrombosis without excessive bleeding. JAMA 1983;249:374.
6. Powers PJ, Gent M, Jay RM, et al. A randomized trial of less intense postoperative warfarin or aspirin therapy, in the prevention of venous thromboembolism after surgery for fractured hip. Arch Intern Med 1989;149:771.
7. Taberner DA, Poller L, Burslem RW, et al. Oral anticoagulants controlled by the British comparative thromboplastin versus low-dose heparin in in prophylaxis of deep vein thrombosis. BMJ 1978;1:272.
8. Poller L, Mc Kernan A, Thomson JM, et al. Fixed minidose warfarin: A new approach to prophylaxis against venous thrombosis after major surgery. BMJ 1987;295:1309.
9. Sheth SB, DiCicco RA, Hursting MJ, et al. Interpreting the international normalized ratio (INR)in individuals receiving argatroban and warfarin. Thromb Haemost 2001; 85:435.
10. Fareed J, Callas D, Hoppensteadt DA, et al. Antithrombin agents as anticoagulants and antithrombotics: Implications in drug development. Semin Hematol 1999;36 (suppl 1):42.
11. Walenga JM, Fasanella AR, Iqbal O, et al. Coagulation laboratory testing in patients treated with argatroban. Semin Thromb Hemost 1999;25(1):61.
12. Greinacher A, Volpel H, Jansens U, et al. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: A prospective study. Circulation 1999;99(1):73.
13. Zoldhelyi P, Webster M, Fuster V, et al. Recombinant hirudin in patients with chronic, stable coronary artery disease. Safety, half-life and effect on coagulation parameters. Circulation 1993;88:2015.
14. Cannon CP, Maraganore JM, Loscalzo J, et al. Anti-coagulant effects of hirulog, a novel thrombin inhibitor, in patients with coronary artery disease. Am J Cardiol 1993;71:778.
15. Hauptman J, Kaiser B, Novak G, et al. Comparison of the anticoagulant and antithrombotic effects of synthetic thrombin and factor Xa inhibitors. Thromb Haemost 1990; 63:220.
16. Fox I, Dawson A, Loynds P, et al. Anticoagulant activity of hirulogTM, a direct thrombin inhibitor in humans. Thromb Haemost 1993;69:157.
17. Bichler J, Ficht B, Siebeck M, et al. Pharmacokinetics and pharmacodynamics of hirudin in man after single subcutaneous and intravenous bolus administration. Arzneim-Forsch/Drug Res 1988;38:704.
18. Rao AK, Sun L, Chesebro JH, et al. Distinct effects of recombinant sesulfato hirudin (Revasc) and heparin on plasma levels of fibrinopeptide A and prothrombin F1.2 in unstable angina: A multicenter trial. Circulation 1996; 94:2389.
19. Nagasawa H, Fukutake K, Hada M, et al. Phase one study of synthetic antithrombin agent (MD-805) single and multiple administration studies. Jpn J Clin Pharmacol Ther 1981;12:359.
20. Callas D, Fareed J. Comparative pharmacology of site-directed antithrombin agents. Implications in drug development. Thromb Haemost 1995;74:473.
21. Hoppensteadt DA, Kahn S, Fareed J. Factor X values as a means to assess the of oral anticoagulation in patients receiving antithrombin drugs. Clin Chem 1997;43:1786.
22. Iqbal O, Tobu M, Fareed D, Hoppensteadt DA, Fareed J. Measurements of thrombin levels using amidolytic anti-IIa assay to monitor oral anticoagulants in patients administered with warfarin and concomitant anti-Xa inhibitors (unpublished data).